PTC Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDPTC Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 70), indicating performance broadly in line with the market. Earnings contraction of 100% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $73.03 | +10.86% | ABOVE |
| 50 SMA | $71.23 | +13.66% | ABOVE |
| 100 SMA | $70.06 | +15.56% | ABOVE |
| 150 SMA | $72.36 | +11.89% | ABOVE |
| 200 SMA | $70.41 | +14.98% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PTCT in an uptrend right now?
PTCT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is PTCT overbought or oversold?
PTCT's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is PTCT outperforming the market?
PTCT has a Relative Strength (RS) Rating of 70 out of 99. PTCT is performing about average compared to the market.
Where is PTCT in its 52-week range?
PTCT is trading at $80.96, which is 93% of its 52-week high ($87.50) and 85% above its 52-week low ($43.18).
How volatile is PTCT?
PTCT has a Beta of 0.84 and 52-week volatility of 43%. It's less volatile than the S&P 500 - generally more stable.